BioMérieux
Boulud also provided additional information on the company's Q4 performance, noting that it placed 900 SpotFire point-of-care PCR instruments during the quarter.
BioMérieux Gets Special 510(k) Clearance From FDA for Tropical Fever Panel
The panel detects pathogens that cause chikungunya, dengue, leptospirosis, and malaria using the firm's BioFire system.
T2 Biosystems Pathogen Detection Patent Upheld in Europe
French diagnostics maker BioMérieux and other undisclosed firms had filed an opposition to the patent in May 2023.
BioMérieux Q2 Revenues Rise 8 Percent
The firm raised its full-year 2024 guidance to sales growth at constant exchange rates of 8 percent to 10 percent, up from previous guidance of 6 percent to 8 percent growth.
At the ADLM annual meeting, firms said they see game-changing opportunities for platforms that provide the right combination of clinical utility and convenience.
May 23, 2024
Apr 12, 2024
Oct 26, 2023
BioMérieux Q3 Revenues Dip Slightly
Sep 1, 2023